| Name | Title | Contact Details |
|---|---|---|
Prashanth Naidu |
Senior Director - IT Governance, Financial Planning and Information Security | Profile |
A&L Catheter Technologies is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Deltagen is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Molecular Devices, we enable our customers to unravel the complexity of biological systems. Our innovative analytical solutions for cell and protein biology enable our customers to see more, do more, and know more, and to answer life`s most important questions. We are one of the world`s leading providers of high-performance bioanalytical measurement solutions for life science research, pharmaceutical and biotherapeutic development. With over 130,000 placements in laboratories around the world, our instruments have catalyzed brilliant scientific research described in over 25,000 peer reviewed publications. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products empower scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Our headquarters are in Silicon Valley, the hub of technology and innovation, with offices around the globe employing close to 1,000 highly skilled and passionate associates.
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx`s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx`s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration. Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two programs: a Phase 1 study of ACLX-001 for r/r MM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, expected to enter the clinic in the second half of 2022.